OCD Augmentation Strategies
On this page
Direct answer
Doses that would conclude a depression trial are where OCD treatment merely begins: fluoxetine 60-80 mg, sertraline 200 mg, fluvoxamine 300 mg, paroxetine 60 mg and clomipramine 225-250 mg are the working targets, and an adequate trial means 8-12 weeks with at least 4-6 of those at the maximum tolerated dose. When a genuinely adequate SSRI course fails, the two evidence-based moves are switching to or adding clomipramine, and combining with exposure and response prevention (ERP), which is the single most powerful step available. Antipsychotic augmentation — risperidone 0.5-2 mg, aripiprazole 10-15 mg — benefits roughly a quarter to a third of patients, most convincingly those with comorbid tics; glutamatergic strategies such as memantine and N-acetylcysteine remain experimental.
What you must remember
- Target doses (memorise the column): fluoxetine 60-80 mg, fluvoxamine up to 300 mg, sertraline 200 mg, paroxetine 60 mg, citalopram 60 mg (QT caution), escitalopram 20 mg, clomipramine 225-250 mg.
- Adequate trial: 8-12 weeks total, with at least 4-6 weeks at maximum tolerated dose; OCD responds roughly half as fast as depression — do not judge at week four.
- First and strongest augmentation: ERP combined with the SSRI; adding structured ERP outperforms adding most drugs.
- Antipsychotic augmentation: risperidone 0.5-2 mg has the best evidence; aripiprazole 10-15 mg is the alternative; comorbid tics are the best predictor of response; benefit is usually visible within weeks — stop if 8 weeks pass without change.
- Clomipramine position: either switch (for SSRI non-responders) or note its near-equivalence in meta-analyses; check ECG and anticholinergic burden.
- Experimental glutamate routes: memantine and N-acetylcysteine 1200-2400 mg/day have small or mixed trials — quote as investigational, not standard.
- Before augmenting anything: verify adherence, dose, duration, and comorbidities (depression, hoarding subtype, poor insight, personality disorder) that predict poorer drug response.
Sequencing treatment after two failed SSRIs
Consider a 24-year-old with contamination obsessions and three-hour showers, eight weeks each on sertraline 200 mg and fluoxetine 80 mg with only partial improvement — Yale-Brown score still 24. The first audit is honesty: were both trials truly full-dose and full-length, was ERP actually delivered (many "failed ERP" patients merely talked about their obsessions without exposure homework)? Assume both were adequate. Option one is cross-tapering to clomipramine 225 mg with ECG and pulse monitoring — the classic switch for double-SSRI failure. Option two is augmenting the better-tolerated SSRI with aripiprazole 10 mg, reviewing at week eight, and discontinuing if Yale-Brown has not moved.
Whichever pharmacological road is taken, ERP intensifies in parallel — therapist-guided exposure to feared contaminants with blocked washing, progressing from moderately to highly distressing items on a hierarchy built with the patient. Response here is usually partial, and the therapeutic contract says so: a fall from 24 to 12 on the Yale-Brown scale with a functioning life is a win, not a failure. Maintenance after response continues for at least 1-2 years; OCD relapse on premature discontinuation is common, and in Indian clinics where follow-up drops off, converting therapy gains into family-supported homework routines materially reduces relapse.
How the exam frames it
The dose table is the examination: "what is the target dose of sertraline in OCD" separates 200 mg from depression's usual ceilings, and clomipramine 225-250 mg appears as an option against its depression dose. The trial-length question catches those who answer with depression's 6 weeks. Augmentation questions embed the tic clue — the stem mentions motor tics and the answer is risperidone add-on. And the duration-of-response principle ("slower onset than depression, weeks not days") is a recurring assertion/reason item where both statement and reason are true and the reason explains the statement.
Frequently asked questions
What doses of SSRIs are targeted in OCD?
Substantially higher than in depression — sertraline 200 mg, fluoxetine 60-80 mg, fluvoxamine up to 300 mg, paroxetine 60 mg — because dose-response continues into these ranges.
How long is an adequate SSRI trial in OCD?
Eight to twelve weeks with at least 4-6 weeks at the maximum tolerated dose; OCD responds more slowly than major depression.
Which augmentation has the best evidence after failed high-dose SSRI?
Combining exposure and response prevention is the strongest step; among drugs, low-dose antipsychotic augmentation (risperidone 0.5-2 mg) has the most support, especially with comorbid tics.
Is there a role for glutamatergic drugs in refractory OCD?
Memantine and N-acetylcysteine have small or mixed studies and are considered experimental rather than standard care — useful to mention, not to promise.
When is clomipramine used in OCD management?
As an alternative first-line agent, or after failure of two adequate SSRI trials — either as a switch or in selected cases combination, with ECG and anticholinergic monitoring.